FDA still open to Cox-2 drugs

04/13/2007 | Reuters

FDA Commissioner Dr. Andrew von Eschenbach said his agency still is willing to consider new Cox-2 pain drugs despite an advisory panel's rejection of Merck's Arcoxia. "We'd be open to any new products coming forward, including Cox-2 inhibitors," he said in an interview. Novartis AG is awaiting an FDA decision on its new COX-2 drug Prexige.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX